Proteomic peptide profiling for preemptive diagnosis of acute graft-versus-host disease after allogeneic stem cell transplantation

Leukemia

Volumn 28, Issue 4, 2014, Pages 842-852

  Weissinger, E M ^a   Metzger, J ^b   Dobbelstein, C ^a   Wolff, D ^c   Schleuning, M ^d   Kuzmina, Z ^e   Greinix, H ^e   Dickinson, A M ^f   Mullen, W ^g   Kreipe, H ^a   Hamwi, I ^a   Morgan, M ^a   Krons, A ^b   Tchebotarenko, I ^a   Ihlenburg Schwarz, D ^a   Dammann, E ^a   Collin, M ^f   Ehrlich, S ^a   Diedrich, H ^a   Stadler, M ^a   Eder, M ^a   Holler, E ^c   Mischak, H ^b   Krauter, J ^a   Ganser, A ^a   more..

^a HANNOVER MEDICAL SCHOOL   (Germany)

^b MOSAIQUES DIAGNOSTICS GMBH   (Germany)

^c UNIVERSITY OF REGENSBURG   (Germany)

^d Division of Gastroenterology   (Germany)

^e MEDICAL UNIVERSITY OF VIENNA   (Austria)

^f NEWCASTLE UNIVERSITY   (United Kingdom)

^g UNIVERSITY OF GLASGOW   (United Kingdom)

Author keywords

capillary electrophoresis; graft versus host disease; hematopoietic stem cell transplantation; mass spectrometry; proteomics

Indexed keywords

ALBUMIN; BETA 2 MICROGLOBULIN; CD99 ANTIGEN; COLLAGEN; FIBRONECTIN; THYMOCYTE ANTIBODY;

ADOLESCENT; ADULT; AGED; ALLOGENEIC STEM CELL TRANSPLANTATION; ARTICLE; CAPILLARY ELECTROPHORESIS; DIAGNOSTIC TEST ACCURACY STUDY; EXTRACELLULAR MATRIX; FEMALE; GRAFT FAILURE; GRAFT RECIPIENT; GRAFT VERSUS HOST REACTION; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; INFLAMMATION; MAJOR CLINICAL STUDY; MALE; MASS SPECTROMETRY; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEOMICS; SENSITIVITY AND SPECIFICITY; T LYMPHOCYTE ACTIVATION; URINALYSIS;

ACUTE DISEASE; ADOLESCENT; ADULT; AGED; FEMALE; GRAFT VS HOST DISEASE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; LOGISTIC MODELS; MALE; MIDDLE AGED; PROTEOMICS; SERUM ALBUMIN; TRANSPLANTATION, HOMOLOGOUS;

EID: 84898490659     PISSN: 08876924     EISSN: 14765551     Source Type: Journal    
DOI: 10.1038/leu.2013.210     Document Type: Article

References (33)

1. Schmid C, Labopin M, Nagler A, Niederwieser D, Castagna L, Tabrizi R et al. Treatment, risk factors, and outcome of adults with relapsed AML after reduced intensity conditioning for allogeneic stem cell transplantation. Blood 2012; 119: 1599-1606.
2. deW T, Brand R, van B A, Mufti G, Ruutu T, Finke J et al. Allogeneic stem cell transplantation for patients with refractory anaemia with matched related and unrelated donors: delay of the transplant is associated with inferior survival. Br J Haematol 2009; 146: 627-636.
3. Kroger N, Brand R, van BA, Zander A, Dierlamm J, Niederwieser D et al. Risk factors for therapy-related myelodysplastic syndrome and acute myeloid leukemia treated with allogeneic stem cell transplantation. Haematologica 2009; 94: 542-549.
4. Young NS, Calado RT, Scheinberg P. Current concepts in the pathophysiology and treatment of aplastic anemia. Blood 2006; 108: 2509-2519.
5. Young NS, Scheinberg P, Calado RT. Aplastic anemia. Curr Opin Hematol 2008; 15: 162-168. (Pubitemid 351507566)
6. Deeg HJ, O'Donnell M, Tolar J, Agarwal R, Harris RE, Feig SA et al. Optimization of conditioning for marrow transplantation from unrelated donors for patients with aplastic anemia after failure of immunosuppressive therapy. Blood 2006; 108: 1485-1491. (Pubitemid 44316112)
7. Holler E. Risk assessment in haematopoietic stem cell transplantation: GvHD prevention and treatment. Best Pract Res Clin Haematol 2007; 20: 281-294. (Pubitemid 46585971)
8. Fuji S, Kapp M, Einsele H. Challenges to preventing infectious complications, decreasing re-hospitalizations, and reducing cost burden in long-term survivors after allogeneic hematopoietic stem cell transplantation. Semin Hematol 2012; 49: 10-14.
9. Wingard JR, Hsu J, Hiemenz JW. Hematopoietic stem cell transplantation: an overview of infection risks and epidemiology. Hematol Oncol Clin North Am 2011; 25: 101-116.
10. Kolb HJ. Graft-versus-leukemia effects of transplantation and donor lymphocytes. Blood 2008; 112: 4371-4383.
11. Ferrara JL, Levine JE, Reddy P, Holler E. Graft-versus-host disease. Lancet 2009; 373: 1550-1561.
12. Finke J, Schmoor C, Bethge WA, Ottinger HD, Stelljes M, Zander AR et al. Prognostic factors affecting outcome after allogeneic transplantation for hematological malignancies from unrelated donors: results from a randomized trial. Biol Blood Marrow Transplant 2012; 18: 1716-1726.
13. Weissinger EM, Mischak H, Ganser A, Hertenstein B. Value of proteomics applied to the follow-up in stem cell transplantation. Ann Hematol 2006; 85: 205-211.
14. Lankisch TO, Metzger J, Negm AA, Vosskuhl K, Schiffer E, Siwy J et al. Bile proteomic profiles differentiate cholangiocarcinoma from primary sclerosing cholangitis and choledocholithiasis. Hepatology 2011; 53: 875-884.
15. Good DM, Zurbig P, Argiles A, Bauer HW, Behrens G, Coon JJ et al. Naturally occurring human urinary peptides for use in diagnosis of chronic kidney disease. Mol Cell Proteomics 2010; 9: 2424-2437.
16. Theodorescu D, Wittke S, Ross MM, Walden M, Conaway M, Just I et al. Discovery and validation of new protein biomarkers for urothelial cancer: a prospective analysis. Lancet Oncol 2006; 7: 230-240. (Pubitemid 43286453)
17. Mischak H, Vlahou A, Ioannidis JP. Technical aspects and inter-laboratory variability in native peptide profiling: the CE-MS experience. Clin Biochem 2013; 46: 432-443.
18. Kaiser T, Kamal H, Rank A, Kolb HJ, Holler E, Ganser A et al. Proteomics applied to the clinical follow-up of patients after allogeneic hematopoietic stem cell transplantation. Blood 2004; 104: 340-349. (Pubitemid 38900013)
19. Weissinger EM, Schiffer E, Hertenstein B, Ferrara JL, Holler E, Stadler M et al. Proteomic patterns predict acute graft-versus-host disease after allogeneic hematopoietic stem cell transplantation. Blood 2007; 109: 5511-5519. (Pubitemid 46890577)
20. Weissinger EM, Mischak H, Kontsendorn J, Hahn A, Hahn N, Morgan M et al. Proteome analysis in hematology using capillary electrophoresis coupled on-line to mass spectrometry. Mini Rev Med Chem 2009; 9: 627-633.
21. Rezvani AR, Storer BE, Storb RF, Mielcarek M, Maloney DG, Sandmaier BM et al. Decreased serum albumin as a biomarker for severe acute graft-versus-host disease after reduced-intensity allogeneic hematopoietic cell transplantation. Biol Blood Marrow Transplant 2011; 17: 1594-1601.
22. Fuji S, Kim SW, Fukuda T, Mori S, Yamasaki S, Morita-Hoshi Y et al. Preengraftment serum C-reactive protein (CRP) value may predict acute graft-versus-host disease and nonrelapse mortality after allogeneic hematopoietic stem cell transplantation. Biol Blood Marrow Transplant 2008; 14: 510-517. (Pubitemid 351494745)
23. Paczesny S, Krijanovski OI, Braun TM, Choi SW, Clouthier SG, Kuick R et al. A biomarker panel for acute graft-versus-host disease. Blood 2009; 113: 273-278.
24. Przepiorka D, Weisdorf D, Martin P, Klingemann HG, Beatty P, Hows J et al. 1994 Consensus conference on acute GVHD grading. Bone Marrow Transplant 1995; 15: 825-828.
25. Jacobsohn DA, Kurland BF, Pidala J, Inamoto Y, Chai X, Palmer JM et al. Correlation between NIH composite skin score, patient reported skin score and outcome: results from the chronic GVHD Consortium. Blood 2012; 120: 2545-2552.
26. Greinix HT, Loddenkemper C, Pavletic SZ, Holler E, Socie G, Lawitschka A et al. Diagnosis and staging of chronic graft-versus-host disease in the clinical practice. Biol Blood Marrow Transplant 2011; 17: 167-175.
27. Theodorescu D, Fliser D, Wittke S, Mischak H, Krebs R, Walden M et al. Pilot study of capillary electrophoresis coupled to mass spectrometry as a tool to define potential prostate cancer biomarkers in urine. Electrophoresis 2005; 26: 2797-2808. (Pubitemid 41078989)
28. Macconi D, Chiabrando C, Schiarea S, Aiello S, Cassis L, Gagliardini E et al. Proteasomal processing of albumin by renal dendritic cells generates antigenic peptides. J Am Soc Nephrol 2009; 20: 123-130.
29. Ferrara JL, Harris AC, Greenson JK, Braun TM, Holler E, Teshima T et al. Regenerating islet-derived 3-alpha is a biomarker of gastrointestinal graft-versushost disease. Blood 2011; 118: 6702-6708.
30. Levine JE, Logan BR, Wu J, Alousi AM, Bolanos-Meade J, Ferrara JL et al. Acute graft-versus-host disease biomarkers measured during therapy can predict treatment outcomes: a Blood and Marrow Transplant Clinical Trials Network study. Blood 2012; 119: 3854-3860.
31. Harris AC, Ferrara JL, Braun TM, Holler E, Teshima T, Levine JE et al. Plasma biomarkers of lower gastrointestinal and liver acute GVHD. Blood 2012; 119: 2960-2963.
32. Finke J, Bethge WA, Schmoor C, Ottinger HD, Stelljes M, Zander AR et al. Standard graft-versus-host disease prophylaxis with or without anti-T-cell globulin in haematopoietic cell transplantation from matched unrelated donors: a randomised, open-label, multicentre phase 3 trial. Lancet Oncol 2009; 10: 855-864.
33. Mohty M. Mechanisms of action of antithymocyte globulin: T-cell depletion and beyond. Leukemia 2007; 21: 1387-1394. (Pubitemid 46965279)